CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $10M, lower than 95% of all stocks globally
- PositionOperating margin is -3704.9%, lower than 95% of its Biotechnology peers (median -23.8%)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.86BUSDvs all stocks (USD)
Revenue (TTM)
10.00MUSDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
52-Week Change
106.65%vs all stocks
Market Capitalization
1.86BUSDvs all stocks (USD)
Enterprise Value
1.41BUSDvs all stocks (USD)
Forward P/E
-13.04xvs Biotechnology peers
Price to Book (MRQ)
5.49xvs Biotechnology peers
Enterprise to Revenue
141.40xvs Biotechnology peers
Enterprise to EBITDA
-5.63xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
-3704.89%vs Biotechnology peers
Return on Assets (TTM)
-29.06%vs Biotechnology peers
Return on Equity (TTM)
-137.11%vs Biotechnology peers
Revenue (TTM)
10.00MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.2236USDUpdated Jul 19, 2026Gross Profit (TTM)
-193.59MUSDvs all stocks (USD)
EBITDA (TTM)
-251.37MUSDvs all stocks (USD)
Net Income (TTM)
-425.15MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-100.00%vs Biotechnology peers
Operating Cash Flow (TTM)
-210.48MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-166.29MUSDvs all stocks (USD)
Payout Ratio
0.00%vs Biotechnology peers
Revenue
10.00MUSDFY2025 · Dec 31, 2025Operating Income
-211.38MUSDvs all stocks (USD)
Pre-tax Income
-377.82MUSDFY2025 · Dec 31, 2025Income Tax Expense
-79.00KUSDFY2025 · Dec 31, 2025Net Income
-377.74MUSDFY2025 · Dec 31, 2025EBIT
-370.49MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-198.76MUSDFY2025 · Dec 31, 2025Research & Development
168.06MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
53.32MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
12.15MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
7.33MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-377.74MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-182.41MUSDFY2025 · Dec 31, 2025Free Cash Flow
-182.42MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
110.64MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-377.74MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
56.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
26.35MUSDFY2025 · Dec 31, 2025Other Non-cash Items
179.87MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-10.04MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-902.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-18.00KUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-35.00MUSDFY2025 · Dec 31, 2025Purchase of Investments
-417.75MUSDFY2025 · Dec 31, 2025Sale of Investments
200.89MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
-216.89MUSDFY2025 · Dec 31, 2025Other Financing Charges
62.34MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
210.91MUSDFY2025 · Dec 31, 2025Shares Outstanding
62.38MSharesUpdated Jul 19, 2026Float Shares
41.06MSharesUpdated Jul 19, 2026Shares Short
12.20MSharesUpdated Jul 19, 2026Short Ratio
13.37daysvs all stocks
Short % of Shares Outstanding
28.80%vs all stocks
% Held by Insiders
18.29%vs all stocks
% Held by Institutions
90.52%vs all stocks
Total Cash (MRQ)
717.20MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
11.36USDUpdated Jul 19, 2026Total Debt (MRQ)
266.83MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.7945xvs Biotechnology peers
Current Ratio (MRQ)
11.94xvs Biotechnology peers
Book Value per Share (MRQ)
5.38USDUpdated Jul 19, 2026Total Assets
383.64MUSDvs all stocks (USD)
Total Current Assets
351.17MUSDFY2025 · Dec 31, 2025Total Liabilities
141.50MUSDFY2025 · Dec 31, 2025Total Non-current Assets
32.47MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
78.85MUSDFY2025 · Dec 31, 2025Total Current Liabilities
62.65MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
110.64MUSDFY2025 · Dec 31, 2025Other Short-term Investments
232.55MUSDFY2025 · Dec 31, 2025Accounts Payable
7.11MUSDFY2025 · Dec 31, 2025Short-term Debt
1.11MUSDFY2025 · Dec 31, 2025Long-term Debt
211.00KUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
78.64MUSDFY2025 · Dec 31, 2025Common Stock (Book)
5.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-765.13MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
242.14MUSDvs all stocks (USD)
52-Week Low
13.50USDUpdated Jul 19, 202652-Week High
44.60USDUpdated Jul 19, 202652-Week Change
106.65%vs all stocks
50-Day MA
21.66USDUpdated Jul 19, 2026200-Day MA
25.34USDUpdated Jul 19, 2026Avg 10-Day Volume
774.50KSharesUpdated Jul 19, 2026Avg 30-Day Volume
966.09KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-9.10USDUpdated Jul 19, 2026Other Income / Expense
-171.25MUSDFY2025 · Dec 31, 2025Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -3704.9%, lower than 95% of its Biotechnology peers (median -23.8%)Significant
Operating margin: -37.05Industry median: -0.24Industry P5: -32.91Peers compared: 197
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.51
Altman Z-Score 2.85: safe zoneNotable
Altman Z-Score: 2.85
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $10M, lower than 95% of all stocks globallySignificant
Revenue (USD): 10,000,000Global P5: 30,274,777.221
Market cap is $1.86B, above the global median of $1.15BNotable
Market cap (USD): 1,864,328,622Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Jafron Biomedical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Yifan Pharmaceutical Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Guobang Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
UFP Technologies Inc.
Tier 1ProductionApproval-Gated PipelineRule
Nanjing Vazyme Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hunan Jingfeng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Mirxes Holding Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Cohance Lifesciences Limited
Tier 1ProductionApproval-Gated PipelineRule
Ascletis Pharma Inc.
Tier 1ProductionApproval-Gated PipelineRule
AbCellera Biologics Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking